BOSTON – Early data on the impact of two insurance benefits programs that offer genetic testing to covered members suggests that such efforts could be a viable strategy to engage people in their care and deliver it in a more personalized fashion.
Despite the step-up by the US Food and Drug Administration in regulatory action on pharmacogenetic testing, the success of these programs, which incorporate PGx, as well as other types of genetic health risk tests, suggests that interest in such tests is growing and access isn't being stifled as some had feared.